THE US Food and Drug Administration has approved a new product called Aimovig (erenumab-aooe) for the preventive treatment of migraine in adults.
The treatment is given by once monthly self-injections.
Among is the first FDA-approved preventive migraine treatment in a new class of drugs that work by blocking the activity of calcitonin gene-related peptide, a molecule that is involved in migraine attacks.
The above article was sent to subscribers in Pharmacy Daily's issue from 22 May 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 May 18
